A study conducted in England and Wales found that demographic factors significantly influenced the initiation of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA). Patients under 40 years old were more than twice as likely to receive these drugs compared to older individuals, while Asian patients were almost half as likely to receive them compared to white patients. Despite fully funded access to these drugs under the NHS, disparities in treatment initiation persist. This study highlights the need for personalized approaches to treatment decisions for RA patients.
Source link
Older, Asian patients less likely to receive b/ts DMARDs for rheumatoid arthritis
